Category: Pharma News

To promote greater transparency and accountability within the ecosystem of organ donation and transplantation, LiveOnNY and MediGO partner to introduce organ monitoring technology.

Using proprietary technology that enables real-time GPS tracking, LiveOnNY, a nonprofit, federally recognised organ procurement organisation, and MediGO, a digital healthcare supply chain technology company, announced that they are collaborating to track organs as they travel across the nation. In…

Ionis’ tofersen may be given accelerated approval by the USFDA for SOD1-ALS, according to the advisory committee’s unanimous vote.

Tofersen, an investigational antisense drug for the treatment of people with superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis, was discussed at the Peripheral and Central Nervous System Drugs Advisory Committee meeting by the US Food and Drug Administration (FDA), according…

When concerns about medication resistance arise, Indian healthcare professionals and pharmaceutical businesses accelerate efforts to treat TB.

When concerns about drug resistance arise, Indian healthcare practitioners and pharmaceutical corporations step up their efforts to control the spread of tuberculosis through early identification and research for new medications. TB poses a serious risk to public health, with an…

The US FDA designates Intellia’s NTLA-2002, a regenerative medicine advanced therapy to treat hereditary angioedema.

The US Food and Drug Administration (FDA) has designated NTLA-2002 for the treatment of hereditary angioedema as a Regenerative Medicine Advanced Treatment (RMAT), according to Intellia Therapeutics, Inc., a leading clinical-stage genome editing business (HAE). NTLA-2002 is a CRISPR-based in…

To treat patients with solid tumours, Sensei Biotherapeutics has submitted an IND application to the US FDA for a phase 1/2 trial of SNS-101.

An investigational new drug (IND) application for SNS-101, a conditionally active VISTA-blocking antibody, has been submitted to the US Food and Drug Administration (FDA) for a phase 1/2 clinical trial in patients with solid tumours, according to Sensei Biotherapeutics, Inc.,…

For the treatment of pancreatic cancer, the US FDA has given Prestige Biopharma’s PBP1510 fast track designation.

The US Food and Drug Administration (FDA) has granted PBP1510 (international non-proprietary name: ulenistamab), a biopharmaceutical product manufactured by Singapore-based Prestige Biopharma, Fast Track designation for the treatment of metastatic or unresectable pancreatic adenocarcinoma (PDAC) that has relapsed after and/or…

Phase 1 patient dosing of PT886 for advanced gastric, gastroesophageal junction, and pancreatic adenocarcinomas is initiated by Phanes Therapeutics.

First patient dosed in phase 1 clinical study (NCT05482893) of PT886, a first-in-class native IgG-like bispecific antibody (bsAb) targeting claudin 18.2 and CD47 for the treatment of gastric, gastroesophageal junction, and pancreatic adenocarcinomas, according to Phanes Therapeutics, Inc. (Phanes), an…

Back to top
WhatsApp Join Telegram